UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 9, 2017
CANTEL MEDICAL CORP.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-31337 |
|
22-1760285 |
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Identification |
|
of incorporation) |
|
File Number) |
|
Number) |
|
150 Clove Road, Little Falls, New Jersey |
|
07424 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (973) 890-7220
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously disclosed, on November 10, 2016, Cantel Medical Corp. (Company) announced that Steven C. Anaya, the then Senior Vice President and Chief Accounting Officer of the Company, would be departing the Company. Mr. Anaya’s last day with the Company was on June 9, 2017.
On June 9, 2017, Brian Capone, Vice President and Corporate Controller of the Company, was named principal accounting officer. Mr. Capone, age 42, joined the Company on April 17, 2017. Prior to that, Mr. Capone served at Stryker Corporation, a medical device company, as the Assistant Corporate Controller from October 2014 through April 2017 and as Director, External Financial Reporting/Technical Accounting at Quest Diagnostics, a clinical lab and diagnostic testing company from April 2012 through October 2014. For more than ten years prior thereto, Mr. Capone served in various finance and accounting positions at both private and public companies. Mr. Capone is a CPA in the state of New York.